RxDoctor Payments Data

Ky le, MD

Internal Medicine · Aiea, HINPI 1073560025

Payments from drug & device makers

$6,144in general payments, 2019–2025

Across 246 payments — averaging $24.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$984
  • AbbVie$850
  • AstraZeneca$837
  • Amgen$717
  • Novo Nordisk$654
  • Sanofi$525
  • plus $2K from 16 others

What the payments were for

  • Food & beverage$6,03598%
  • Education$1092%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,144 in reported general payments places this provider in the 85th percentile of 655 internal medicine providers in Hawaii.

See all internal medicine providers in Hawaii

Medicare billing

Part B allowed, 2024
$121,748
Medicare patients
138
Services billed
10,867

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dupixent PenDupilumab12$46,129
MounjaroTirzepatide31$37,330
EntrestoSacubitril/Valsartan27$30,531
JardianceEmpagliflozin34$29,340
EliquisApixaban36$23,724
ProliaDenosumab12$20,359
Repatha SyringeEvolocumab11$7,302
Rosuvastatin Calcium39$1,352
Atorvastatin Calcium102$1,293
Amlodipine Besylate100$1,027
Pantoprazole Sodium49$958
Dexamethasone68$703
Tamsulosin Hcl46$684
Albuterol Sulfate HfaAlbuterol Sulfate33$661
Metoprolol Succinate57$628

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$984$37,33031 claims
NovartisEntresto$127$30,53127 claims
Boehringer IngelheimJardiance$23$29,34034 claims
PfizerEliquis$131$23,72436 claims
AmgenProlia$717$20,35912 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 655 internal medicine providers in Hawaii.

Other internal medicine in Aiea

See the full list for Hawaii

Where these figures come from

Is this you, or does something look wrong? →